

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

**STA Tagraxofusp for treating blastic plasmacytoid
dendritic cell neoplasm**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

Stakeholders highlighted that blastic plasmacytoid dendritic cell neoplasm is more common in men than in women.

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee? |
|---|

NICE considers that this cannot be addressed within this technology appraisal because guidance on the use of tagraxofusp would not be able to address this issue. The committee will appraise tagraxofusp in line with the marketing authorisation, which is unlikely to have restrictions by gender.

- | |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|--|

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

Approved by Associate Director (name): Nicole Elliott

Date: 06/05/2020